Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients without septic shock (98,109,110).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [109]
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [171]
In the citing paper
“Multivariate analysis in this study also provided a strong association between delay in therapy and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [46]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 11×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“of inappropriate initial treatment [6].”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 5×
“Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
BackgroundResultInfluentialAttributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 1×
“[1].”
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437 · cited 2×
“attributable mortality remains 19%–49% [2, 5].”
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331 · cited 10×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of 8 cases per 100,000 population [2–4].”
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155 · cited 1×
“Development of nonculture methods for the rapid diagnosis of candidemia in patients with BSI may also significantly improve the ability to quickly prescribe appropriate antifungal therapy [19, 20].”
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Cited by
Items 101–200 of 1,000
Pfaller, M. A., Diekema, D. J., Procop, G. W., & Rinaldi, M. G. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00403-07 · Cited by 135
“The availability of rapid, quantitative antifungal susceptibility data will be a major step in optimizing the therapy of invasive candidal infections (1, 14, 16, 19, 23).”
BackgroundSherry, L., Rajendran, R., Lappin, D. F., Borghi, E., Perdoni, F., Falleni, M., Tosi, D., Smith, K., Williams, C., Jones, B., et al. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-182 · Cited by 134
“Given the importance of these infections, efficient and appropriate treatment in candidaemia cases has been highlighted [29,30], as failure to treat quickly and effectively has profound consequences on mortality statistics [31].”
BackgroundMALDI-TOF mass spectrometry in the clinical mycology laboratory: identification of fungi and beyond
Posteraro, B., De Carolis, E., Vella, A., & Sanguinetti, M. (2013) · Expert Review of Proteomics · doi:10.1586/epr.13.8 · Cited by 128
Pinto, A. N., Halliday, C. L., Zahra, M., van Hal, S., Olma, T., Maszewska, K., Iredell, J. R., Meyer, W., & Chen, S. C. ‐. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025712 · Cited by 149
“albicans Candida and non-Candida yeasts are resistant or less susceptible to antifungal agents, rapid accurate species identification is central to timely, effective antifungal therapy [3–6,8,9].”
BackgroundDiagnosis of invasive candidiasis in the ICU
Eggimann, P., Bille, J., & Marchetti, O. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-37 · Cited by 131
“Therapy of candidemia delayed beyond 12 h after sampling of blood has been associated with an increase of in-hospital mortality from < 20% to 40% [26,27].”
BackgroundAntifungal serum concentration monitoring: an update
Goodwin, M. L., & Drew, R. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm389 · Cited by 141
The risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 134
“The limitations of our database are the restriction to one city, the lack of information regarding severity of illness, the duration of candidemic period, central venous catheter removal [26], lack of consideration of antifungal dosing issues [47–49], and delayed initiation of adequate antifungal therapy [47, 50, 51],…”
BackgroundEllis, M., al-Ramadi, B., Finkelman, M., Hedstrom, U., Kristensen, J., Ali-Zadeh, H., & Klingspor, L. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47479-0 · Cited by 131
“…(IFI) and their attendant high mortality dictate that early, empirical antifungal therapy in the persistently febrile neutropenic patient remains the practice standard (Pizzo et al., 1982; EORTC International Antimicrobial Therapy Cooperative Group, 1989; Walsh et al., 1999; Garey et al., 2006).”
BackgroundThe case for antifungal stewardship
Ananda-Rajah, M. R., Slavin, M. A., & Thursky, K. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834e0680 · Cited by 136
Healthcare Epidemiology: Does Antibiotic Selection Impact Patient Outcome?
Harbarth, S., Junior, V. A. N., & Pittet, D. (2006) · Clinical Infectious Diseases · doi:10.1086/510075 · Cited by 144
“Delay in initiating antifungal treatment for critically ill patients may also be associated with worse outcomes [24].”
Guinea, J., Zaragoza, Ó., Escribano, P., Martín-Mazuelos, E., Pemán, J., Sánchez-Reus, F., & Cuenca-Estrella, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02155-13 · Cited by 131
“Although rapid and prompt starting of antifungal therapy is important in order to improve the outcome for the patients (6), resistance may contribute to treatment failures.”
BackgroundPfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 129
“Delays in administering effective antifungal therapy (right drug and right dose) directly influence mortality (28, 29, 52, 59), and such local epidemiological data provide the best way to optimize early initial antifungal therapy (21, 56, 59, 80).”
BackgroundPfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Zilberberg, M. D., Kollef, M. H., Arnold, H., Labelle, A., Micek, S. T., Kothari, S., & Shorr, A. F. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-150 · Cited by 128
“cohort, where they documented increasing mortality based on the delay, measured in days from when the culture was drawn to antifungal treatment [7].”
BackgroundAntifungal stewardship considerations for adults and pediatrics
Hamdy, R. F., Zaoutis, T. E., & Seo, S. K. (2016) · Virulence · doi:10.1080/21505594.2016.1226721 · Cited by 132
Effect of antifungal therapy timing on mortality in cancer patients with candidemia
Taur, Y., Cohen, N., Dubnow, S., Paskovaty, A., & Seo, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00945-09 · Cited by 127
“(13) have shown that delaying antifungal therapy for the treatment of candidemia is associated with increased mortality.”
BackgroundResultInfluentialThe Epidemiology and Diagnosis of Invasive Candidiasis Among Premature Infants
Kelly, M. S., Benjamin, D. K., & Smith, P. B. (2014) · Clinics in Perinatology · doi:10.1016/j.clp.2014.10.008 · Cited by 139
“Delayed initiation of appropriate antifungal therapy is associated with increased mortality from invasive candidiasis.(61,62) However, the identification of infants with candi-”
Obeng, A. O., Egelund, E. F., Alsultan, A., Peloquin, C. A., & Johnson, J. A. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1400 · Cited by 137
Lau, A., Halliday, C., Chen, S. C.-A., Playford, E. G., Stanley, K., & Sorrell, T. C. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01650-09 · Cited by 118
“The early initiation of targeted antifungal therapy is essential for improving patient outcomes (8, 26).”
BackgroundYealy, D. M., Mohr, N. M., Shapiro, N. I., Venkatesh, A. K., Jones, A. E., & Self, W. H. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.02.006 · Cited by 136
Böhme, A., Ruhnke, M., Buchheidt, D., Cornely, O. A., Einsele, H., Enzensberger, R., Hebart, H. F., Heinz, W., Junghanß, C., Karthaus, M., et al. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0622-5 · Cited by 141
“Due to high mortality, especially in patients with delayed sufficient treatment [24], antifungal treatment should be started in neutropenic patients as soon as possible.”
BackgroundOvercoming antifungal resistance
Srinivasan, A., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.02.005 · Cited by 144
Grim, S. A., Berger, K., Teng, C., Gupta, S., Layden, J. E., Janda, W. M., & Clark, N. M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr511 · Cited by 118
Inhibition of Filamentation Can Be Used To Treat Disseminated Candidiasis
Saville, S. P., Lazzell, A. L., Bryant, A. P., Fretzen, A., Monreal, A., Solberg, E. O., Monteagudo, C., Lopez-Ribot, J. L., & Milne, G. T. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00628-06 · Cited by 115
“In support of similar observations with conventional antifungal agents in animal models (7), and also with patients with disseminated candidiasis (4, 8), our data reinforce the need for prompt diagnosis and therapeutic intervention in at-risk patients.”
ResultGuery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1339-6 · Cited by 117
“This hypothesis may be supported by the recent studies suggesting that early institution of adequate antifungal therapy may significantly reduce mortality in patients with candidemia, as described above [3, 4, 6].”
ResultFluconazole Loading Dose Pharmacokinetics and Safety in Infants
Piper, L., Smith, P. B., Hornik, C. P. V., Cheifetz, I. M., Barrett, J. S., Moorthy, G., Hope, W. W., Wade, K. C., Cohen‐Wolkowiez, M., & Benjamin, D. K. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318202cbb3 · Cited by 126
“Prompt administration of antifungal therapy can improve outcomes in candidemic patients.(2,3) Despite prompt therapy, 20% of young infants with candidiasis die as a result of invasive disease.”
BackgroundSurviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Racil, Z., Kocmanova, I., Lengerova, M., Weinbergerova, B., Buresova, L., Toskova, M., Winterova, J., Timilsina, S., Rodriguez, I., & Mayer, J. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.019299-0 · Cited by 115
“Early diagnosis and the initiation of efficacious antifungal treatments are major factors in contributing to the prognosis of patients with IFIs (Garey et al., 2006; von Eiff et al., 1995).”
BackgroundMejia-Chew, C., O'Halloran, J. A., Olsen, M. A., Stwalley, D., Kronen, R., Lin, C., Salazar, A. S., Larson, L., Hsueh, K., Powderly, W. G., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30405-0 · Cited by 113
Gómez, C. A., Budvytiene, I., Zemek, A., & Banaei, N. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix728 · Cited by 117
An approach to antibiotic treatment in patients with sepsis
Martínez, M. L., Plata-Menchaca, E. P., Ruiz‐Rodríguez, J. C., & Ferrer, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.47 · Cited by 135
“There are many studies on the effects of delayed administration of antibiotics in patients with sepsis and septic shock (27-32).”
BackgroundGarnacho-Montero, J., Diaz-Martin, A., Garcia-Cabrera, E., Ruiz Perez de Pipaon, M., Hernandez-Caballero, C., & Lepe-Jimenez, J. A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks347 · Cited by 112
Deresinski, S. C. (2007) · Clinical Infectious Diseases · doi:10.1086/519472 · Cited by 114
“Recent studies have found similar improved survival among patients with candidemia who received antifungal therapy in a timely fashion [8, 9].”
ResultHost response to Candida albicans bloodstream infection and sepsis
Duggan, S., Leonhardt, I., Hünniger, K., & Kurzai, O. (2015) · Virulence · doi:10.4161/21505594.2014.988096 · Cited by 97
“This is related to the fact that Candida bloodstream infections—although showing a high mortality—do not fulfill classical diagnostic criteria for sepsis and septic shock in most cases.(5,17,18) (Table 1).”
BackgroundTreatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“133 ,135,136 The IDSA recommends consideration of fluconazole or echinocandin prophylaxis for high-risk ICU patients in units with >5% rate of invasive candidiasis.”
BackgroundClinical and Therapeutic Aspects of Candidemia: A Five Year Single Centre Study
Bassetti, M., Merelli, M., Ansaldi, F., de Florentiis, D., Sartor, A., Scarparo, C., Callegari, A., & Righi, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127534 · Cited by 105
“The increase of the attributable mortality of candidemia has driven research into the role of early diagnosis and prompt treatment initiation in order to improve outcomes [21,22].”
BackgroundMellinghoff, S. C., Hoenigl, M., Koehler, P., Kumar, A., Lagrou, K., Lass‐Flörl, C., Meis, J. F., Menon, V., Rautemaa‐Richardson, R., & Cornely, O. A. (2018) · Mycoses · doi:10.1111/myc.12746 · Cited by 99
Wang, H., Xiao, M., Chen, S. C.-A., Kong, F., Sun, Z.-Y., Liao, K., Lu, J., Shao, H.-F., Yan, Y., Fan, H., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01130-12 · Cited by 105
“Early and appropriate antifungal therapy is essential for optimum patient outcomes in invasive yeast infections (13, 26).”
BackgroundTime to positive culture and identification for Candida blood stream infections
Fernandez, J., Erstad, B. L., Petty, W., & Nix, D. E. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.04.002 · Cited by 106
Fungal diagnosis: how do we do it and can we do better?
Perfect, J. R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761134 · Cited by 120
Candida Infections in Solid Organ Transplantation
Silveira, F. P., & Kusne, S. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12114 · Cited by 113
The Candidemia Study Group, Barchiesi, F., Orsetti, E., Gesuita, R., Skrami, E., & Manso, E. (2015) · Infection · doi:10.1007/s15010-015-0845-z · Cited by 113
“Here, we confirmed that an appropriate antifungal therapy started within 72 h from the first blood culture performed is significantly associated with a lower 30-day mortality [26, 36, 37].”
BackgroundCandida in Solid Organ Transplant Recipients
Pappas, P. G., & Silveira, F. P. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02909.x · Cited by 111
Knitsch, W., Vincent, J.-L., Utzolino, S., François, B., Dinya, T., Dimopoulos, G., Özgüneş, İ., Valía, J. C., Eggimann, P., León, C., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ707 · Cited by 100
“Early antifungal treatment reduces mortality rates in patients with documented IC [4, 5], but a swift definitive diagnosis is difficult [6, 7].”
BackgroundOxman, D. A., Chow, J. K., Frendl, G., Hadley, S., Hershkovitz, S., Ireland, P., McDermott, L. A., Tsai, K., Marty, F. M., Kontoyiannis, D. P., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq136 · Cited by 105
Multicenter Study Evaluating the Vitek MS System for Identification of Medically Important Yeasts
Westblade, L. F., Jennemann, R., Branda, J. A., Bythrow, M., Ferraro, M. J., Garner, O. B., Ginocchio, C. C., Lewinski, M. A., Manji, R., Mochon, A. B., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00680-13 · Cited by 104
What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Elbehiry, A., Aldubaib, M., Abalkhail, A., Marzouk, E., ALbeloushi, A., Moussa, I. M., Ibrahem, M. D., Albazie, H. H., Alqarni, A., Anagreyyah, S. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10111881 · Cited by 104
“Clinical outcomes have been demonstrated to be improved, and hospital stays to be shortened as a result [90,91].”
BackgroundAntifungal therapy in invasive fungal infections
Chen, S. C. ‐., Playford, E. G., & Sorrell, T. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.002 · Cited by 109
“In particular, the appropriateness and timing of empiric antifungal therapy appears to be an important predictor of outcome [17,19].”
BackgroundSystemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
Leroy, O., Bailly, S., Gangneux, J.-P., Mira, J.-P., Devos, P., Dupont, H., Montravers, P., Perrigault, P.-F., Constantin, J.-M., Guillemot, D., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-015-0103-7 · Cited by 102
“glabrata, which is the leading non-albicans pathogen in France [19, 21], in Northern European countries [22–24], and in the US [11, 25].”
BackgroundMethod for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS
Alffenaar, J. C., Wessels, A. M. A., van Hateren, K., Greijdanus, B., Kosterink, J. G. W., & Uges, D. R. A. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.11.017 · Cited by 109
Sofjan, A. K., Mitchell, A., Shah, D. N., Nguyen, T., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.013 · Cited by 95
Self-citationManagement of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100
Early treatment of candidemia in adults: a review
Ostrosky-Zeichner, L., Kullberg, B. J., Bow, E. J., Hadley, S., León, C., Nucci, M., Patterson, T. F., & Perfect, J. R. (2011) · Medical Mycology · doi:10.3109/13693786.2010.512300 · Cited by 97
Baker, S. N., Acquisto, N. M., Ashley, E. D., Fairbanks, R. J. T., Beamish, S. E., & Haas, C. E. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011420160 · Cited by 94
“There is data in the inpatient setting that reveal time to appropriate antibiotics does play a role in patient outcomes.(11-13) The purpose of this investigation was to compare the number of days to culture follow-up and patient or provider notification and appropriate antimicrobial therapy before and after an EPh-man…”
BackgroundSchroeder, M., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00755-8 · Cited by 89
“Although there is strong evidence that a delay in treatment negatively affects outcome, the optimal time point of intervention, such as central venous catheter (CVC) removal, is under debate [13, 14].”
BackgroundHospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia
Arnold, H. M., Micek, S. T., Shorr, A. F., Zilberberg, M. D., Labelle, A. J., Kothari, S., & Kollef, M. H. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.4.361 · Cited by 94
Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries
Kaur, H., & Chakrabarti, A. (2017) · Journal of Fungi · doi:10.3390/jof3030041 · Cited by 93
“5–2 times patients survive) in adults in ICU [110,111,126].”
BackgroundDeterminants of mortality in non-neutropenic ICU patients with candidaemia.
Marriott, D. J., Playford, E. G., Chen, S., Slavin, M., Nguyen, Q., Ellis, D., Sorrell, T. C., & Study, T. A. C. (2009) · Critical Care · doi:10.1186/cc7964 · Cited by 93
“In contrast, the other relevant study [8] did demonstrate increases in mortality for delays measured in 24-hour increments.”
BackgroundResultInfluentialPaiva, J.-A., Pereira, J. M., Tabah, A., Mikstacki, A., de Carvalho, F. B., Koulenti, D., Ruckly, S., Çakar, N., Misset, B., Dimopoulos, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1229-1 · Cited by 84
“[29], mortality doubles when antifungal agents are administered ≥12 hours after the collection of the first positive blood culture and in another retrospective analysis of 230 patients with candidemia [30], initiation of fluconazole ≤24 hours after the first positive blood culture was associated with a significantly l…”
BackgroundThe effect of time to antifungal therapy on mortality in candidemia associated septic shock
Patel, G. P., Simon, D., Scheetz, M., Crank, C. W., Lodise, T., & Patel, N. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181a1afb7 · Cited by 92
“In one study, mortality among candidemic patients was directly related to delays in the initiation of fluconazole therapy.(9) Another study revealed that antifungal therapy administered within 12 hours of drawing a positive blood culture for Candida led to improved survival among patients with CBSI.”
BackgroundKumar, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr090 · Cited by 92
Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study
Johnson, M. D., Plantinga, T. S., van de Vosse, E., Velez Edwards, D. R., Smith, P. B., Alexander, B. D., Yang, J. C., Kremer, D., Laird, G. M., Oosting, M., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir827 · Cited by 93
Invasive candidiasis in intensive care units in China: a multicentre prospective observational study
Guo, F., Yang, Y., Kang, Y., Zang, B., Cui, W., Qin, B., Qin, Y., Fang, Q., Qin, T., Jiang, D., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt083 · Cited by 92
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Cortegiani, A., Russotto, V., Maggiore, A., Attanasio, M., Naro, A. R., Raineri, S. M., & Giarratano, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004920.pub3 · Cited by 91
Bloos, F., Sachse, S., Kortgen, A., Pletz, M. W., Lehmann, M. N., Straube, E., Riedemann, N. C., Reinhart, K., & Bauer, M. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046003 · Cited by 91
“Faster microbiological workup could reduce the possibly fatal consequences of inappropriate antimicrobial therapy [6].”
BackgroundDrug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
Kumar, A. (2014) · Virulence · doi:10.4161/viru.26913 · Cited by 86
Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients
Eschenauer, G. A., Kwak, E. J., Humar, A., Potoski, B. A., Clarke, L. G., Shields, R. K., Abdel-Massih, R., Silveira, F. P., Verhidis, P., Clancy, C. J., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.12993 · Cited by 85
“Most importantly, the low attributable mortality in our study and others (Table S2) suggests that prophylaxis attenuates the severity of IFIs that do develop (21,22).”
BackgroundSupplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
(2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89
Antifungal drug resistance: do molecular methods provide a way forward?
Perlin, D. S. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283321ce5 · Cited by 89
“Clinical outcomes are improved when treatment is started early [ 12 ,13], but empiric antifungal therapy has unwanted consequences as it increases selective pressure toward drug-resistant species [3,14].”
BackgroundCurrent Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 84
Zhang, S. X., Babady, N. E., Hanson, K. E., Harrington, A., Larkin, P. M. K., Leal, S. M., Luethy, P. M., Martin, I. W., Pancholi, P., Procop, G. W., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01784-20 · Cited by 90
“Delayed diagnosis and initiation of inappropriate antifungal treatment are associated with higher mortality rates (64).”
BackgroundIriart, X., Lavergne, R., Fillaux, J., Valentin, A., Magnaval, J., Berry, A., & Cassaing, S. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06713-11 · Cited by 99
“An early treatment which considers the fungal species and any potential resistance is required to successfully treat these infections (5, 8, 14).”
BackgroundHermsen, E. D., Zapapas, M. K., Maiefski, M., Rupp, M. E., Freifeld, A. G., & Kalil, A. C. (2011) · Critical Care · doi:10.1186/cc10366 · Cited by 82
“Due to the appreciable morbidity, mortality and costs associated with invasive candidiasis and the implications of delayed appropriate antifungal therapy, the use of clinical prediction rules to help determine in which high-risk patients prophylactic antifungal therapy may be beneficial is of interest [2,4-7].”
BackgroundFarmakiotis, D., Kyvernitakis, A., Tarrand, J. J., & Kontoyiannis, D. P. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.07.006 · Cited by 86
“Indeed, the high mortality associated with candidaemia in the present and previous [7,8,14] reports can be attributed to the long time that is needed for culture-based diagnosis [26].”
BackgroundCandidaemia in internal medicine departments: the burden of a rising problem
Bassetti, M., Molinari, M. P., Mussap, M., Viscoli, C., & Righi, E. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12155 · Cited by 89
Kohlmann, R., Hoffmann, A., Geis, G., & Gatermann, S. G. (2015) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.04.004 · Cited by 86
“Thus, even though rapid dentification of yeasts would be desirable as mortality of fungal loodstream infection is high especially in the event of delayed ntifungal therapy (Garey et al., 2006), our protocol does unforunately not provide this opportunity.”
BackgroundEmergence of non-albicans candida species in neonatal candidemia
Juyal, D., Sharma, M., Pal, S., Rathaur, V., & Sharma, N. (2013) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.118919 · Cited by 84
“[1] Also removal of catheter alone is not sufficient and administration of antifungal agents is equally important as early treatment with antifungals is associated with enhanced survival.[28,29] However in the present study, both these factors were frequent as majority of neonates who died had delay in the initiation…”
BackgroundRajendran, R., Sherry, L., Deshpande, A., Johnson, E. M., Hanson, M. F., Williams, C., Munro, C. A., Jones, B. L., & Ramage, G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00915 · Cited by 81
Fraser, M., Brown, Z., Houldsworth, M., Borman, A. M., & Johnson, E. M. (2015) · Medical Mycology · doi:10.1093/mmy/myv085 · Cited by 86
Antworth, A., Collins, C. D., Kunapuli, A., Klein, K. C., Carver, P. L., Gandhi, T. N., Washer, L., & Nagel, J. L. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1186 · Cited by 85
Lorente, L., Jiménez, A., Santana, M. C., Iribarren, J. L., Jiménez, J. J., Martin, M. M. I. D. O., & Mora, M. L. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000284589.63641.b8 · Cited by 95
“Recent studies have shown the importance of early antifungal therapy (17, 18).”
BackgroundInvasive fungal infections in patients with cancer in the Intensive Care Unit
Sipsas, N. V., & Kontoyiannis, D. P. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.017 · Cited by 81
“Early (empirical or pre-emptive) therapy for invasive candidiasis in intensive care unit patients with cancer—Results of retrospective studies have shown that reduced times to treatment of IC are correlated with reduced mortality rates [16].”
BackgroundT2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward
Clancy, C. J., & Nguyen, M. H. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky050 · Cited by 84
Chen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Cai, D., Xiao, M., Xu, P., Xu, Y., & Du, W. (2014) · Lab on a Chip · doi:10.1039/c4lc00669k · Cited by 82
Santolaya, M. E., Matute, T. A., Queiroz‐Telles, F., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson, L., Guzman, M. F., Sifuentes‐Osornio, J., et al. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000039 · Cited by 81
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80
“The importance of early, effective empiric therapy for patients with IC is now well recognized (Garey et al., 2006; Klevay et al., 2009; Morrell et al., 2005; Pappas et al., 2009; Parkins et al., 2007).”
BackgroundBeyda, N. D., Alam, M. J., & Garey, K. W. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.07.007 · Cited by 84
“As a delay in the diagnosis and treatment of candidemia is associated with increased mortality and healthcare costs, a more rapid method of detection is urgently needed (Garey et al., 2006;Morrell et al., 2005).”
MethodSelf-citationEmerging trends in candidemia: A higher incidence but a similar outcome
Fortün, J., Martín‐Dávila, P., de la Pedrosa, E. G., Pintado, V., Cobo, J., Fresco, G., Meije, Y., Ros, L., Álvarez, M. E. D., Luengo, J. D. M. L., et al. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.02.011 · Cited by 92
T2Candida for the Diagnosis and Management of Invasive Candida Infections
Monday, L., Acosta, T. J. P., & Alangaden, G. J. (2021) · Journal of Fungi · doi:10.3390/jof7030178 · Cited by 78
“Invasive candidiasis has significant attributable mortality and early antifungal treatment is associated improved outcomes [3,4].”
BackgroundPolymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Infections
Kourkoumpetis, T. K., Fuchs, B. B., Coleman, J. J., Desalermos, A. P., & Mylonakis, E. E. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis132 · Cited by 85
Time to positivity of blood cultures of different Candida species causing fungaemia
Lai, C.-C., Wang, C.-Y., Liu, W.-L., Huang, Y.-T., & Hsueh, P.-R. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.038166-0 · Cited by 74
“, 2005) and that delayed administration of appropriate antifungal therapy has significant adverse effects on the outcome of patients with candidaemia (Morrell et al., 2005; Garey et al., 2006).”
BackgroundPfaller, M. A., Diekema, D. J., Procop, G. W., & Rinaldi, M. G. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01986-06 · Cited by 78
“The availability of rapid quantitative antifungal susceptibility data will be a major step in optimizing the therapy of invasive candidal infections (1, 13, 15, 18).”
BackgroundPreventing invasive candida infections. Where could we do better?
Eggimann, P., Que, Y.-A., Revelly, J.-P., & Pagani, J.-L. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.11.006 · Cited by 74
Pahwa, N., Kumar, R., Nirkhiwale, S., & Bandi, A. (2014) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.124300 · Cited by 83
Metadata
- Authors
- Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T.
- Affiliations
- University of Houston (US)
- University of New Mexico (US)
- Baptist Memorial Health Care (US)
- University of Tennessee Health Science Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oregon State University (US)
- Corresponding author
- Garey, Kevin W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 25-31
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164001967
- Semantic Scholar
- e1a67fd5e540307550577ea7a071370b075e943f
- Cited by
- 1,171
- References
- 20
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 31 · 2023: 31 · 2022: 49 · 2021: 67 · 2020: 51 · 2019: 51 · 2018: 62 · 2017: 66 · 2016: 61 · 2015: 74 · 2014: 87 · 2013: 83 · 2012: 77
- FWCI
- 35.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Enzon Pharmaceuticals
- University of Houston
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, fluconazole, treatment delay, mortality, fungemia, Candida albicans, APACHE II score, mortality risk factors, hospitalized patients, Candida tropicalis, Candida parapsilosis, Candida glabrata, diabetes mellitus, cancer patients, sepsis
- MeSH terms
- Adult, Aged, Antifungal Agents, Candidiasis, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.